Lex M. Cowsert
Oprichter bij Bellairepharma, Inc.
Profiel
Lex M.
Cowsert is the founder.
He founded Bellairepharma, Inc. in 2007 and currently holds the title of Chief Scientific Officer.
Dr. Cowsert's former job includes being the President, Chief Executive Officer & Director at Cytogenix, Inc. from 2008 to 2010.
In terms of education, Dr. Cowsert completed his undergraduate degree at the University of Florida and obtained a doctorate from Georgetown University in 1987.
Actieve functies van Lex M. Cowsert
Bedrijven | Functie | Begin |
---|---|---|
Bellairepharma, Inc. | Oprichter | 03-12-2009 |
Eerdere bekende functies van Lex M. Cowsert
Bedrijven | Functie | Einde |
---|---|---|
Cytogenix, Inc.
Cytogenix, Inc. Miscellaneous Commercial ServicesCommercial Services CytoGenix, Inc. focuses on development and commercialization of its proprietary technology for identify and silencing disease causing genes and expressing proteins for applications. The company was founded on February 10, 1995 and is headquartered in Houston, TX. | President | 27-10-2010 |
Automated Cell, Inc.
Automated Cell, Inc. Pharmaceuticals: MajorHealth Technology Automated Cell, Inc. provides drug discovery services to the pharmaceutical and biotechnology markets. The company uses automated cell biology tools for improving the productivity of therapeutic development in cell therapy & drug discovery. It focuses on the development of monoclonal antibody therapeutics for the treatment of cancer. The company was founded by Raymond K. Houck & Dr. Paul DiMilla in 1998 and is headquartered in Pittsburgh, PA. | Hoofd Techniek/Wetenschap/O&O | 05-04-2010 |
IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
VistaGen Therapeutics, Inc. /Old/
VistaGen Therapeutics, Inc. /Old/ BiotechnologyHealth Technology VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen's Clinical Trials in a Test Tube platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions. | Corporate Officer/Principal | - |
HoustonPharma, Inc.
HoustonPharma, Inc. Pharmaceuticals: MajorHealth Technology HoustonPharma, Inc. develops pharmaceutical products and technologies. It develops oncolytic virus technologies for the treatment of cancer, including ovarian cancer, glioblastoma, and multiple myeloma. The company is headquartered in Malvern, PA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Lex M. Cowsert
Georgetown University | Doctorate Degree |
University of Florida | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Automated Cell, Inc.
Automated Cell, Inc. Pharmaceuticals: MajorHealth Technology Automated Cell, Inc. provides drug discovery services to the pharmaceutical and biotechnology markets. The company uses automated cell biology tools for improving the productivity of therapeutic development in cell therapy & drug discovery. It focuses on the development of monoclonal antibody therapeutics for the treatment of cancer. The company was founded by Raymond K. Houck & Dr. Paul DiMilla in 1998 and is headquartered in Pittsburgh, PA. | Health Technology |
HoustonPharma, Inc.
HoustonPharma, Inc. Pharmaceuticals: MajorHealth Technology HoustonPharma, Inc. develops pharmaceutical products and technologies. It develops oncolytic virus technologies for the treatment of cancer, including ovarian cancer, glioblastoma, and multiple myeloma. The company is headquartered in Malvern, PA. | Health Technology |
VistaGen Therapeutics, Inc. /Old/
VistaGen Therapeutics, Inc. /Old/ BiotechnologyHealth Technology VistaGen Therapeutics, Inc. is a South San Francisco-based biotechnology company that focuses on providing clinically relevant, commercially scalable, human stem cell biology-based screening systems capable of predicting the safety and efficacy of new drugs in ways never before possible. VistaGen's Clinical Trials in a Test Tube platform is designed to generate predictive information that results in reduced probability of clinical trial drug failures, especially failures associated with heart and liver toxicity. VistaGen expects its new-generation stem cell-based human systems biology platform to enhance dramatically the pharmaceutical industry's ability to deliver innovative drugs for some of the world's most challenging diseases and conditions. | Health Technology |
Bellairepharma, Inc. | |
Cytogenix, Inc.
Cytogenix, Inc. Miscellaneous Commercial ServicesCommercial Services CytoGenix, Inc. focuses on development and commercialization of its proprietary technology for identify and silencing disease causing genes and expressing proteins for applications. The company was founded on February 10, 1995 and is headquartered in Houston, TX. | Commercial Services |